Aratana Therapeutics (Aratana Therapeutics) Short Interest

View and export this data going back to 2013. Start your Free Trial

What is Aratana Therapeutics Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Aratana Therapeutics's Short Interest

For the Biotechnology subindustry, Aratana Therapeutics's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Aratana Therapeutics's Short Interest Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aratana Therapeutics's Short Interest distribution charts can be found below:

* The bar in red indicates where Aratana Therapeutics's Short Interest falls into.

Aratana Therapeutics (Aratana Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aratana Therapeutics Inc (NAS:PETX) » Definitions » Short Interest

Comparable Companies

Traded in Other Exchanges

N/A

Address

11400 Tomahawk Creek Parkway, Suite 340, Leawood, KS, USA, 66211

Website

http://www.aratana.com

Aratana Therapeutics Inc is a pet therapeutics company. Its main activity is the licensing, developing, and commercializing of innovative biopharmaceutical products for companion animals. The company's portfolio consists of therapeutic candidates such as small-molecule pharmaceuticals and large-molecule biologics. The main product candidates in development comprise small-molecule pharmaceuticals directed at treating osteoarthritis pain, inflammation, appetite stimulation, and post-operative pain. The firm's strategy consists of licensing proprietary technology from human biopharmaceutical companies or academia to develop therapeutics specifically for use in pets.

Executives

Roche Robert P Jr	director	41 MOORES ROAD FRAZER PA 19355
Vort John Vander	director	C/O MPM ASSET MANAGEMENT, 200 CLARENDON STREET 54TH FLOOR, BOSTON MA 02116
Lowell W Robinson	director	470 WEST END AVENUE, NEW YORK NY 10024
Wendy L Yarno	director
David L Brinkley	director	901 GATEWAY BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Merilee Raines	director	IDEXX LABORATORIES, INC., ONE IDEXX DRIVE, WESTBROOK ME 04092
Kevin Kotler	10 percent owner	C/O BROADFIN CAPITAL, LLC, 300 PARK AVENUE, 25TH FLOOR, NEW YORK NY 10022
Broadfin Capital, Llc	10 percent owner	300 PARK AVENUE, 25TH FLOOR, NEW YORK NY 10022
Broadfin Healthcare Master Fund Ltd	10 percent owner	C/O 20 GENESIS CLOSE, ANSBACHER HOUSE, 2ND FLOOR, PO BOX 1344, GRAND CAYMAN E9 KY1-1108
Craig A. Barbarosh	director	3525 PIEDMONT RD., NE, BUILDING 6, SUITE 700, ATLANTA GA 30305
Hockaday Irvine O Jr	director	SPRINT NEXTEL CORPORATION, 2001 EDMUND HALLEY DRIVE, RESTON VA 20191
Craig A Tooman	director, officer: President and CEO
Peter Steven St	director, officer: PRESIDENT AND CEO	MPM CAPITAL, 200 CLARENDON STREET 54TH FLOOR, BOSTON MA 02116
Laura Brege	director	C/O ONYX PHARMACEUTICALS, INC., 2100 POWELL STREET, EMERYVILLE CA 94608
Jay Lichter	director	C/O ARATANA THERAPEUTICS, INC., 11400 TOMAHAWK CREEK PARKWAY, SUITE 340, LEAWOOD KS 66211